- Home
- VTRS vs MRNA Comparison
VTRS vs MRNA Comparison
Compare VTRS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTRS
- MRNA
- Stock Information
- Founded
- VTRS 1961
- MRNA 2010
- Country
- VTRS United States
- MRNA United States
- Employees
- VTRS N/A
- MRNA N/A
- Industry
- VTRS Medicinal Chemicals and Botanical Products
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTRS Health Care
- MRNA Health Care
- Exchange
- VTRS Nasdaq
- MRNA Nasdaq
- Market Cap
- VTRS 12.2B
- MRNA 9.2B
- IPO Year
- VTRS N/A
- MRNA 2018
- Fundamental
- Price
- VTRS $10.13
- MRNA $24.36
- Analyst Decision
- VTRS Hold
- MRNA Hold
- Analyst Count
- VTRS 6
- MRNA 15
- Target Price
- VTRS $11.17
- MRNA $36.69
- AVG Volume (30 Days)
- VTRS 8.9M
- MRNA 11.9M
- Earning Date
- VTRS 11-06-2025
- MRNA 11-06-2025
- Dividend Yield
- VTRS 4.74%
- MRNA N/A
- EPS Growth
- VTRS N/A
- MRNA N/A
- EPS
- VTRS N/A
- MRNA N/A
- Revenue
- VTRS $14,124,400,000.00
- MRNA $2,232,000,000.00
- Revenue This Year
- VTRS N/A
- MRNA N/A
- Revenue Next Year
- VTRS $1.61
- MRNA $10.38
- P/E Ratio
- VTRS N/A
- MRNA N/A
- Revenue Growth
- VTRS N/A
- MRNA N/A
- 52 Week Low
- VTRS $6.85
- MRNA $23.04
- 52 Week High
- VTRS $13.55
- MRNA $56.70
- Technical
- Relative Strength Index (RSI)
- VTRS 44.58
- MRNA 43.32
- Support Level
- VTRS $10.24
- MRNA $23.48
- Resistance Level
- VTRS $10.95
- MRNA $25.56
- Average True Range (ATR)
- VTRS 0.27
- MRNA 1.46
- MACD
- VTRS -0.02
- MRNA -0.32
- Stochastic Oscillator
- VTRS 12.14
- MRNA 15.89
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.